Literature DB >> 26471484

Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen.

Ruth M de Tute1, Andy C Rawstron1, Walter M Gregory2, J Anthony Child2, Faith E Davies3, Sue E Bell2, Gordon Cook1, Alexander J Szubert2, Mark T Drayson4, Graham H Jackson5, Gareth J Morgan3, Roger G Owen6.   

Abstract

Entities:  

Keywords:  flow cytometry; induction; minimal residual disease; myeloma

Mesh：

Substances：

Year:  2015        PMID： 26471484      PMCID： PMC4938335          DOI： 10.3324/haematol.2015.128215

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.

Authors:  Bruno Paiva; Maria-Belén Vidriales; Jorge Cerveró; Gema Mateo; Jose J Pérez; Maria A Montalbán; Anna Sureda; Laura Montejano; Norma C Gutiérrez; Alfonso García de Coca; Natalia de Las Heras; Maria V Mateos; Maria C López-Berges; Raimundo García-Boyero; Josefina Galende; Jose Hernández; Luis Palomera; Dolores Carrera; Rafael Martínez; Javier de la Rubia; Alejandro Martín; Joan Bladé; Juan J Lahuerta; Alberto Orfao; Jesús F San Miguel
Journal:  Blood       Date:  2008-07-31       Impact factor: 22.113

2.  Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium.

Authors:  Ola Landgren; Nicole Gormley; Danielle Turley; Roger G Owen; Andy Rawstron; Bruno Paiva; David Barnett; Maria Arroz; Paul Wallace; Brian Durie; Constance Yuan; Ahmet Dogan; Maryalice Stetler-Stevenson; Gerald E Marti
Journal:  Am J Hematol       Date:  2014-12       Impact factor: 10.047

Review 3.  Minimal residual disease in multiple myeloma: bringing the bench to the bedside.

Authors:  Sham Mailankody; Neha Korde; Alexander M Lesokhin; Nikoletta Lendvai; Hani Hassoun; Maryalice Stetler-Stevenson; Ola Landgren
Journal:  Nat Rev Clin Oncol       Date:  2015-01-27       Impact factor: 66.675

4.  Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.

Authors:  Gareth J Morgan; Faith E Davies; Walter M Gregory; Sue E Bell; Alexander J Szubert; Nuria Navarro Coy; Gordon Cook; Sylvia Feyler; Peter R E Johnson; Claudius Rudin; Mark T Drayson; Roger G Owen; Fiona M Ross; Nigel H Russell; Graham H Jackson; J Anthony Child
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

5.  High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.

Authors:  Bruno Paiva; Norma C Gutiérrez; Laura Rosiñol; María-Belén Vídriales; María-Ángeles Montalbán; Joaquín Martínez-López; María-Victoria Mateos; María-Teresa Cibeira; Lourdes Cordón; Albert Oriol; María-José Terol; María-Asunción Echeveste; Raquel de Paz; Felipe de Arriba; Luis Palomera; Javier de la Rubia; Joaquín Díaz-Mediavilla; Anna Sureda; Ana Gorosquieta; Adrian Alegre; Alejandro Martin; Miguel T Hernández; Juan-José Lahuerta; Joan Bladé; Jesús F San Miguel
Journal:  Blood       Date:  2011-11-29       Impact factor: 22.113

6.  Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.

Authors:  Sebastian Böttcher; Matthias Ritgen; Kirsten Fischer; Stephan Stilgenbauer; Raymonde M Busch; Günter Fingerle-Rowson; Anna Maria Fink; Andreas Bühler; Thorsten Zenz; Michael Karl Wenger; Myriam Mendila; Clemens-Martin Wendtner; Barbara F Eichhorst; Hartmut Döhner; Michael J Hallek; Michael Kneba
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

7.  Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.

Authors:  Andy C Rawstron; J Anthony Child; Ruth M de Tute; Faith E Davies; Walter M Gregory; Sue E Bell; Alexander J Szubert; Nuria Navarro-Coy; Mark T Drayson; Sylvia Feyler; Fiona M Ross; Gordon Cook; Graham H Jackson; Gareth J Morgan; Roger G Owen
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544

8.  Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment.

Authors:  Gareth J Morgan; Faith E Davies; Walter M Gregory; Susan E Bell; Alexander J Szubert; Gordon Cook; Mark T Drayson; Roger G Owen; Fiona M Ross; Graham H Jackson; J Anthony Child
Journal:  Clin Cancer Res       Date:  2013-08-30       Impact factor: 12.531

9.  Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction.

Authors:  Andy C Rawstron; Walter M Gregory; Ruth M de Tute; Faith E Davies; Sue E Bell; Mark T Drayson; Gordon Cook; Graham H Jackson; Gareth J Morgan; J Anthony Child; Roger G Owen
Journal:  Blood       Date:  2015-02-02       Impact factor: 22.113
  9 in total
  19 in total

1.  The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype.

Authors:  Carolina Schinke; Antje Hoering; Hongwei Wang; Victoria Carlton; Sharmilan Thanandrarajan; Shayu Deshpande; Purvi Patel; Gabor Molnar; Sandra Susanibar; Meera Mohan; Pankaj Mathur; Muthukumar Radhakrishnan; Shadiqul Hoque; Jorge Jo Kamimoto; Monica Grazziutti; Frits van Rhee; Maurizio Zangari; Giovanni Insuasti-Beltran; Daisy Alapat; Ginell Post; Shmuel Yaccoby; Joshua Epstein; Leo Rasche; Sarah Johnson; Martin Moorhead; Tom Willis; Bart Barlogie; Brian Walker; Niels Weinhold; Faith E Davies; Gareth J Morgan
Journal:  Haematologica       Date:  2017-05-18       Impact factor: 9.941

2.  MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods.

Authors:  Mikhail Roshal; Juan A Flores-Montero; Qi Gao; Maesa Koeber; Jessica Wardrope; Brian G M Durie; Ahmet Dogan; Alberto Orfao; Ola Landgren
Journal:  Blood Adv       Date:  2017-05-03

Review 3.  Is molecular remission the goal of multiple myeloma therapy?

Authors:  Faith E Davies
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

4.  Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials.

Authors:  P Arana; B Paiva; M-T Cedena; N Puig; L Cordon; M-B Vidriales; N C Gutierrez; F Chiodi; L Burgos; L-L Anglada; J Martinez-Lopez; M-T Hernandez; A-I Teruel; M Gironella; M-A Echeveste; L Rosiñol; R Martinez; A Oriol; J De la Rubia; A Orfao; J Blade; J-J Lahuerta; M-V Mateos; J-F San Miguel
Journal:  Leukemia       Date:  2017-11-03       Impact factor: 11.528

5.  Quantification of bone-marrow plasma cell levels using various International Myeloma Working Group response criteria in patients with multiple myeloma.

Authors:  Kentaro Narita; Hiroki Kobayashi; Yoshiaki Abe; Hiroaki Kitadate; Masami Takeuchi; Kosei Matsue
Journal:  Int J Hematol       Date:  2018-07-05       Impact factor: 2.490

Review 6.  Myeloma in Elderly Patients: When Less Is More and More Is More.

Authors:  Ashley Rosko; Sergio Giralt; Maria-Victoria Mateos; Angela Dispenzieri
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

7.  The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents.

Authors:  R Chakraborty; E Muchtar; S Kumar; F K Buadi; D Dingli; A Dispenzieri; S R Hayman; W J Hogan; P Kapoor; M Q Lacy; N Leung; M A Gertz
Journal:  Bone Marrow Transplant       Date:  2016-08-22       Impact factor: 5.483

Review 8.  BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.

Authors:  Sarah A Holstein; Hervé Avet-Loiseau; Theresa Hahn; Christine M Ho; Jens G Lohr; Nikhil C Munshi; Bruno Paiva; Marcelo C Pasquini; Joseph D Tario; Saad Z Usmani; Paul K Wallace; Katja Weisel; Philip L McCarthy
Journal:  Biol Blood Marrow Transplant       Date:  2017-12-11       Impact factor: 5.742

9.  Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma.

Authors:  Dilan A Patel; Ragisha Gopalakrishnan; Brian G Engelhardt; Evonne McArthur; Salyka Sengsayadeth; Katie A Culos; Michael Byrne; Stacey Goodman; Bipin N Savani; Wichai Chinratanalab; Madan Jagasia; Claudio A Mosse; Robert F Cornell; Adetola A Kassim
Journal:  Bone Marrow Transplant       Date:  2020-01-28       Impact factor: 5.483

10.  Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.

Authors:  Juan-Jose Lahuerta; Bruno Paiva; Maria-Belen Vidriales; Lourdes Cordón; Maria-Teresa Cedena; Noemi Puig; Joaquin Martinez-Lopez; Laura Rosiñol; Norma C Gutierrez; María-Luisa Martín-Ramos; Albert Oriol; Ana-Isabel Teruel; María-Asunción Echeveste; Raquel de Paz; Felipe de Arriba; Miguel T Hernandez; Luis Palomera; Rafael Martinez; Alejandro Martin; Adrian Alegre; Javier De la Rubia; Alberto Orfao; María-Victoria Mateos; Joan Blade; Jesus F San-Miguel
Journal:  J Clin Oncol       Date:  2017-05-12       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.